Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juris J Meier

Showing results (31-40 of 144) with videos related to

Pageof 15
Sort By:
Diabetes|May 28, 2005
Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humansJuris J Meier, Johannes D Veldhuis, Peter C Butler
Critical Care (London, England)|July 11, 2013
The gut-brain axis in the critically ill: is glucagon-like peptide-1 protective in neurocritical care?Mark P Plummer, Juris J Meier, Adam M Deane
Journal of Diabetes Science and Technology|August 19, 2020
Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal VariabilityAnna M Lindmeyer, Juris J Meier, Michael A Nauck
Journal of Diabetes Science and Technology|October 22, 2019
Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII)Michael A Nauck, Anna M Lindmeyer, Chantal Mathieu, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|October 29, 2021
The incretin/glucagon system as a target for pharmacotherapy of obesityStefano Del Prato, Baptist Gallwitz, Jens Juul Holst, et al.
Regulatory Peptides|July 26, 2002
Gastric inhibitory polypeptide: the neglected incretin revisitedJuris J Meier, Michael A Nauck, Wolfgang E Schmidt, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|August 15, 2019
Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy - A Retrospective Observational StudyChristina Buchholz, Melanie Kahle-Stephan, Juris J Meier, et al.
European Journal of Pharmacology|May 15, 2002
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectivesJuris J Meier, Baptist Gallwitz, Wolfgang E Schmidt, et al.
Diabetes|March 25, 2011
Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humansMichael A Nauck, Guido Kemmeries, Jens J Holst, et al.
Diabetes|June 29, 2005
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjectsJuris J Meier, Guido Kemmeries, Jens J Holst, et al.
Pageof 15

Showing results (31-40 of 144) with videos related to

Sort By:
Pageof 15
Diabetes|May 28, 2005
Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humansJuris J Meier, Johannes D Veldhuis, Peter C Butler
Critical Care (London, England)|July 11, 2013
The gut-brain axis in the critically ill: is glucagon-like peptide-1 protective in neurocritical care?Mark P Plummer, Juris J Meier, Adam M Deane
Journal of Diabetes Science and Technology|August 19, 2020
Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal VariabilityAnna M Lindmeyer, Juris J Meier, Michael A Nauck
Journal of Diabetes Science and Technology|October 22, 2019
Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII)Michael A Nauck, Anna M Lindmeyer, Chantal Mathieu, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|October 29, 2021
The incretin/glucagon system as a target for pharmacotherapy of obesityStefano Del Prato, Baptist Gallwitz, Jens Juul Holst, et al.
Regulatory Peptides|July 26, 2002
Gastric inhibitory polypeptide: the neglected incretin revisitedJuris J Meier, Michael A Nauck, Wolfgang E Schmidt, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|August 15, 2019
Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy - A Retrospective Observational StudyChristina Buchholz, Melanie Kahle-Stephan, Juris J Meier, et al.
European Journal of Pharmacology|May 15, 2002
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectivesJuris J Meier, Baptist Gallwitz, Wolfgang E Schmidt, et al.
Diabetes|March 25, 2011
Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humansMichael A Nauck, Guido Kemmeries, Jens J Holst, et al.
Diabetes|June 29, 2005
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjectsJuris J Meier, Guido Kemmeries, Jens J Holst, et al.
Pageof 15